Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections
Ibrahim Turkoz,1 Mehmet Daskiran,1 H Lynn Starr,2 Dean Najarian,2 Oliver Lopena,2 Camilo Obando,2 Alexander Keenan,3 Carmela Benson,3 Srihari Gopal4 1Statistics & Decision Sciences, Janssen Research and Development, LLC, Titusville, NJ, USA; 2Neuroscience, Janssen Scientific Affairs, LLC, Titusv...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-08-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/comparing-relapse-rates-in-real-world-patients-with-schizophrenia-who--peer-reviewed-fulltext-article-NDT |
| _version_ | 1797998976841023488 |
|---|---|
| author | Turkoz I Daskiran M Starr HL Najarian D Lopena O Obando C Keenan A Benson C Gopal S |
| author_facet | Turkoz I Daskiran M Starr HL Najarian D Lopena O Obando C Keenan A Benson C Gopal S |
| author_sort | Turkoz I |
| collection | DOAJ |
| description | Ibrahim Turkoz,1 Mehmet Daskiran,1 H Lynn Starr,2 Dean Najarian,2 Oliver Lopena,2 Camilo Obando,2 Alexander Keenan,3 Carmela Benson,3 Srihari Gopal4 1Statistics & Decision Sciences, Janssen Research and Development, LLC, Titusville, NJ, USA; 2Neuroscience, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Real World Value & Evidence, Neuroscience, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 4Schizophrenia/Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, USACorrespondence: Ibrahim Turkoz, Statistics & Decision Sciences, Janssen Research & Development, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA, Tel +1 609-730-7719, Fax +1 609-730-3232, Email ITukoz@its.jnj.comPurpose: This retrospective cohort study evaluated real-world data on relapses in adult patients with schizophrenia who transitioned to long-acting injectable paliperidone palmitate once-every-3-months (PP3M) following treatment with once-monthly paliperidone palmitate (PP1M).Patients and Methods: Data derived from the IBM® MarketScan® Multi-State Medicaid Database were analyzed. Adults aged ≥ 18 years with ≥ 1 schizophrenia diagnosis claim and ≥ 12 months of continuous medical and prescription enrollment before and/or at index date of PP3M were eligible for inclusion. Patients were matched on propensity score to 2 PP3M cohorts: (1) adequately treated (AT), defined as patients treated with PP1M for ≥ 4 months, with the last 2 doses the same and a PP3M initiation dose meeting the corresponding PP1M-to-PP3M dose conversion, or (2) not adequately treated (NAT), defined as patients who received ≤ 2 or no PP1M doses. Relapse rates and time to relapse distributions based on the first occurrence of a qualifying event during the 2-year follow-up period were compared between PP3M cohorts using Kaplan–Meier survival curves and log rank test statistics. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Two sensitivity analyses using different matched populations were performed to assess the robustness of the primary findings.Results: Propensity score matching yielded a sample of 1314 patients (657 per group). Most patients were male (68.9%) and aged 25– 64 years (90.1%). The relapse rate was significantly lower in the AT (18.4%) versus NAT cohort (26.8%), P = 0.0002. Risk of relapse decreased by 35% for AT versus NAT (HR: 0.65 [95% CI: 0.51– 0.81]). Relapse reductions favored the AT cohort in both sensitivity analyses (HR: 0.67 [95% CI: 0.54– 0.83] and HR: 0.74 [95% CI: 0.56– 0.97]).Conclusion: In this analysis of Medicaid claims data, patients adequately treated with PP1M before transitioning to PP3M demonstrated significantly lower relapse rates and delayed time to relapse.Keywords: paliperidone palmitate, schizophrenia, real-world, relapse, long-acting injectable antipsychotic |
| first_indexed | 2024-04-11T10:57:23Z |
| format | Article |
| id | doaj.art-612f5a9ab58146b797910e02495ce460 |
| institution | Directory Open Access Journal |
| issn | 1178-2021 |
| language | English |
| last_indexed | 2024-04-11T10:57:23Z |
| publishDate | 2022-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj.art-612f5a9ab58146b797910e02495ce4602022-12-22T04:28:43ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212022-08-01Volume 181927193777783Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months InjectionsTurkoz IDaskiran MStarr HLNajarian DLopena OObando CKeenan ABenson CGopal SIbrahim Turkoz,1 Mehmet Daskiran,1 H Lynn Starr,2 Dean Najarian,2 Oliver Lopena,2 Camilo Obando,2 Alexander Keenan,3 Carmela Benson,3 Srihari Gopal4 1Statistics & Decision Sciences, Janssen Research and Development, LLC, Titusville, NJ, USA; 2Neuroscience, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Real World Value & Evidence, Neuroscience, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 4Schizophrenia/Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, USACorrespondence: Ibrahim Turkoz, Statistics & Decision Sciences, Janssen Research & Development, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA, Tel +1 609-730-7719, Fax +1 609-730-3232, Email ITukoz@its.jnj.comPurpose: This retrospective cohort study evaluated real-world data on relapses in adult patients with schizophrenia who transitioned to long-acting injectable paliperidone palmitate once-every-3-months (PP3M) following treatment with once-monthly paliperidone palmitate (PP1M).Patients and Methods: Data derived from the IBM® MarketScan® Multi-State Medicaid Database were analyzed. Adults aged ≥ 18 years with ≥ 1 schizophrenia diagnosis claim and ≥ 12 months of continuous medical and prescription enrollment before and/or at index date of PP3M were eligible for inclusion. Patients were matched on propensity score to 2 PP3M cohorts: (1) adequately treated (AT), defined as patients treated with PP1M for ≥ 4 months, with the last 2 doses the same and a PP3M initiation dose meeting the corresponding PP1M-to-PP3M dose conversion, or (2) not adequately treated (NAT), defined as patients who received ≤ 2 or no PP1M doses. Relapse rates and time to relapse distributions based on the first occurrence of a qualifying event during the 2-year follow-up period were compared between PP3M cohorts using Kaplan–Meier survival curves and log rank test statistics. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Two sensitivity analyses using different matched populations were performed to assess the robustness of the primary findings.Results: Propensity score matching yielded a sample of 1314 patients (657 per group). Most patients were male (68.9%) and aged 25– 64 years (90.1%). The relapse rate was significantly lower in the AT (18.4%) versus NAT cohort (26.8%), P = 0.0002. Risk of relapse decreased by 35% for AT versus NAT (HR: 0.65 [95% CI: 0.51– 0.81]). Relapse reductions favored the AT cohort in both sensitivity analyses (HR: 0.67 [95% CI: 0.54– 0.83] and HR: 0.74 [95% CI: 0.56– 0.97]).Conclusion: In this analysis of Medicaid claims data, patients adequately treated with PP1M before transitioning to PP3M demonstrated significantly lower relapse rates and delayed time to relapse.Keywords: paliperidone palmitate, schizophrenia, real-world, relapse, long-acting injectable antipsychotichttps://www.dovepress.com/comparing-relapse-rates-in-real-world-patients-with-schizophrenia-who--peer-reviewed-fulltext-article-NDTpaliperidone palmitateschizophreniareal-worldrelapselong-acting injectable antipsychotic |
| spellingShingle | Turkoz I Daskiran M Starr HL Najarian D Lopena O Obando C Keenan A Benson C Gopal S Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections Neuropsychiatric Disease and Treatment paliperidone palmitate schizophrenia real-world relapse long-acting injectable antipsychotic |
| title | Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections |
| title_full | Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections |
| title_fullStr | Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections |
| title_full_unstemmed | Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections |
| title_short | Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections |
| title_sort | comparing relapse rates in real world patients with schizophrenia who were adequately versus not adequately treated with paliperidone palmitate once monthly injections before transitioning to once every 3 months injections |
| topic | paliperidone palmitate schizophrenia real-world relapse long-acting injectable antipsychotic |
| url | https://www.dovepress.com/comparing-relapse-rates-in-real-world-patients-with-schizophrenia-who--peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT turkozi comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT daskiranm comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT starrhl comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT najariand comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT lopenao comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT obandoc comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT keenana comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT bensonc comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections AT gopals comparingrelapseratesinrealworldpatientswithschizophreniawhowereadequatelyversusnotadequatelytreatedwithpaliperidonepalmitateoncemonthlyinjectionsbeforetransitioningtoonceevery3monthsinjections |